Skip to the navigation. Skip to the content. Login | Contact Us | Links

MRCG: Medical Research Charities Group

Unity is Our Strength
  • Home
  • About Us
    • Our Board
    • Our Staff
    • Governance
    • Privacy Policy
    • Contact Us
  • Our Work
    • Joint Funding Scheme
    • Advocacy
    • Member Support
    • PPI
    • IHRF
    • Patient Registries
    • Rare Diseases
    • Intellectual Property
    • Working With Industry
  • Joint Funding Scheme
    • How it works
    • Timeline
    • Open Calls
    • Scheme Impact
    • Testimonials
    • Past Rounds
    • Project Examples
  • Our Members
  • Become a Member
    • Benefits of Membership
    • Membership Criteria
    • Membership Enquiry Form
  • News & Events
    • Events
    • Newsletter
    • News
    • MRCG Blog
    • MRCG Videos
  • Publications
    • Templates
    • Recommendations
    • Guides
    • Reports
    • Policy Submissions
    • Open Consultations
    • MRCG Conference Papers
    • Workshop Presentations
    • Advocacy
    • Pre-budget Submissions
    • Useful Links
You are here: Home > Joint Funding Scheme > Scheme Impact
Joint Funding Scheme
  • How it works
  • Timeline
  • Open Calls
  • Scheme Impact
  • Testimonials
  • Past Rounds
  • Project Examples

Impact of the HRB/MRCG Joint Funding Scheme 2014/2015

  • The MRCG Co-fund scheme had 4% of the funding allocation, and accounted for 4% of total publications. The average number of papers per grant was 2.6 (similar to Project Grants and Fellowship Awards), with 14 papers per €1 million spent, at a cost per paper of €71k.
  • Presentations (both oral and poster) at scientific meetings were the most common scientific dissemination type reported. Recipients of the MRCG Co-fund and Infrastructure awards were the most active in this regard.
  • Of all grant types, the MRCG Co-fund scheme produced the highest number of oral and poster presentations (national and international) per €1 million spend.
  • The MRCG Co-fund scheme created 17 posts at a cost of €130k each, with 8 posts created on average per €1 million spent.
  • The MRCG Co-fund awards were almost exclusively categorised as Applied Biomedical Research (one was combined Applied Biomedical and Clinical Research), and attracted primarily biomedical scientists, as well as one technician and two medical doctors.
  • The MRCG Co-fund award, while accounting for only 10% of total reports of prizes, awards and recognition, yielded an average of 16.3 awards, prizes or recognition outputs per €1 million spend, by far the most productive of all the grant types.
  • The most productive grant type was the MRCG Co-fund, which produced 12 collaborations per €1 million spend. 22 of the 27 MRCG collaborations were with academic partners, both national and international, while the majority of the remaining seven collaborations were with international health service providers. 
  • Holders of MRCG Co-fund awards reported securing 19 additional awards, valued at 3.8% of the total value of leveraged awards. This represented a good return on investment of €721K for every €1 million spend on this grant type. 
  • Finally, the MRCG Co-fund scheme was the most productive in terms of policy and practice outputs (3.2 per €1 million spend) even though the majority (96%) of MRCG Co-fund awards were categorised as Applied Biomedical Research, and might not be expected to have a focus on this metric.

 

Post: Digital Office Centre, 12 Camden Row, Dublin 8, D08 R9CN Tel: 01 479 3234  
Cha
rity number:
CHY 15386 Registered company number: 377794  CRA number: 20052973






               
 
Twitter
web design by ionic